Amikacin sulfate PR is a Small Molecule owned by Insmed, and is involved in 14 clinical trials, of which 12 were completed, and 2 are ongoing.

Amikacin is an aminoglycoside antibiotic. Aminoglycosides irreversibly binds to and inhibits specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anti-codon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Arikace can be delivered through nebulization, which enables the small aerosol droplet size to facilitate more effective distribution in the lungs.

The revenue for Amikacin sulfate PR is expected to reach a total of $14.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Amikacin sulfate PR NPV Report.

Amikacin sulfate PR is currently owned by Insmed.

Amikacin sulfate PR Overview

Amikacin sulfate (Arikayce) is a semi-synthetic aminoglycoside derivative of kanamycin, acts as an anti-bacterial agent. It is formulated as sustained release liposomal suspension for inhalational route of administration. Arikayce is indicated for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.

Amikacin sulfate (Arikace) is under development for lung infections due to nontuberculous mycobacteria infections caused by Mycobacterium avium complex (MAC), non-MAC nontuberculous mycobacterium species. Arikace is a liposomal formulation of the antibiotic amikacin. Liposomal amikacin for inhalation (Arikace) is a sustained-release formulation of amikacin encapsulated inside nano-scale liposomal carriers designed for administration via inhalation. Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 16S rRNA of the 30S ribosomal subunit, causing misreading of tRNA, leaving the bacterium unable to synthesize proteins vital to its growth. It is administered with a handled eFlow nebulizer with lower systemic exposure. It was also under development for the treatment of Pseudomonas lung infections in cystic fibrosis patients in the U.S, EU and Canada and non-CF bronchiectasis caused by pseudomonas aeruginosa.

Insmed Overview

Insmed is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib for non-cystic fibrosis (non-CF) bronchiectasis, cystic fibrosis and COVID-19; TPIP, an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company operates in the US, the UK, the Netherlands, Ireland, Italy, Germany, France and Japan through its subsidiaries. Insmed is headquartered in Bridgewater, New Jersey, the US.

The company reported revenues of (US Dollars) US$188.5 million for the fiscal year ended December 2021 (FY2021), an increase of 14.6% over FY2020. The operating loss of the company was US$392.8 million in FY2021, compared to an operating loss of US$265.2 million in FY2020. The net loss of the company was US$434.7 million in FY2021, compared to a net loss of US$294.1 million in FY2020. The company reported revenues of US$67.7 million for the third quarter ended September 2022, an increase of 3.8% over the previous quarter.

Quick View – Amikacin sulfate PR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Amikacin sulfate PR
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.